BioCentury on BioBusiness,
Analyst Picks & Changes
Analyst picks & changes
Published on
Monday, March 19, 2012
|
Company
|
Bank
|
Analyst
|
Coverage
|
Opinion
|
Wk
chg
|
3/16
cls
|
|
Anthera
Pharmaceuticals Inc. (NASDAQ:ANTH)
|
Cowen
|
Steve
Scala
|
Downgrade
|
Neutral
(from outperform)
|
-51%
|
$3.17
|
|
|
Deutsche
Bank
|
Navdeep
Singh
|
Price
target
|
Buy
|
|
|
|
|
Piper
Jaffray
|
Edward
Tenthoff
|
Price
target
|
Overweight
|
|
|
|
|
Summer
Street
|
Carol
Werther
|
Price
target
|
Buy
|
|
|
|
|
Wedbush
|
Duane
Nash
|
Price
target
|
Outperform
|
|
|
|
Scala
downgraded after Anthera said it would discontinue development of
cardiovascular compound varespladib for all indications after it showed a
lack of efficacy in the Phase III VISTA-16 trial to treat acute coronary
syndrome (ACS). Anthera made the decision based on a recommendation from a
DSMB (see BioCentury, March 12). Anthera's next most advanced product
is blisibimod, which is in the Phase IIb PEARL-SC trial to treat systemic
lupus erythematosus (SLE). Final data are expected in 2Q12. Scala believes
the lupus market is "poorly defined," noting that recently launched
lupus drugs "failed to meet the Street expectations with no improvement
in sight." Varespladib is a secretory phospholipase A2 (sPLA2) inhibitor
and blisibimod is a peptide fusion protein that antagonizes BLyS (BAFF).
|
170
words displayed of
788
words total.
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Current Subscribers
If you are a current subscriber, log in below or in the upper right corner of this
page.
Log In
Subscription Option
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
records.
close [ X ]